Health ❯ Obesity

Medications

GLP-1 Drugs GLP-1 Anti-Obesity Drugs GLP-1 Agonists Pharmaceuticals GLP-1 Receptor Agonists Weight Management Patient Access Cardiometabolic Diseases Wegovy Anti-obesity Drugs Oral Drugs Semaglutide Tirzepatida Drug Shortages Employer Coverage GLP-1 Therapies Pharmaceutical Industry Clinical Trials Market Competition Semaglutide and Tirzepatide Reimbursement

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

The case seeks to curb Eli Lilly’s consumer ads and could change how head‑to‑head trial results are shown to patients and prescribers.

Rutgers Study Finds Current GLP‑1 Use Linked to Weaker Paths From Impulse and Alcohol to Violence

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping